Dr. Went, founding CEO and Chairman of Adamas Pharmaceuticals, has overseen the development of the company since its inception. Previously, Dr. Went co-founded CuraGen Corporation in 1992, where he served as an Executive Vice President and Director. Dr. Went received his Ph.D. in Chemical Engineering from the University of California, Berkeley, and a B.S. in Chemical Engineering from Carnegie Mellon University and is the author of 28 papers and an inventor on more than 70 patents and patent applications.
Mr. Bigham currently serves as Chief Executive Officer and Chairman of the Board of Directors of Paratek Pharmaceuticals, Inc. He has more than 25 years of senior leadership experience in the biopharmaceutical industry. From 2003 to 2015, Mr. Bigham was a partner at Abingworth LLP, an international investment group dedicated to life sciences and healthcare. Earlier in his career, he served as Chairman and Chief Executive Officer of Coulter Pharmaceuticals up until the company’s acquisition by Corixa. Mr. Bigham currently is a member of the Board of Directors of InMediata and has held several directorships, including Avila Therapeutics, Magellan Biosciences, Portola Pharmaceuticals, Supernus Pharmaceuticals, Avedro and Valeritas. He received his B.S. from the University of Virginia and his M.B.A. from Stanford University.
Mr. Booth is a senior advisor in the financial services industry, currently serving multiple companies including Century Capital Management LLC, WorldBusiness Capital, Inc., Priority Care Solutions LLC and Cyence LLC. He is a director of The Hanover Insurance Group and Patient Matters LLC. From July 2009 through February 2014, Mr. Booth was Vice Chairman of Guy Carpenter LLC., a wholly owned subsidiary of Marsh and McLennan Companies, Inc. Previously, Mr. Booth held senior positions with several large companies in the insurance and financial services industry. Mr. Booth is a CPA, CLU and ChFC and is a member of numerous professional organizations. He is a National Association of Corporate Directors Board Leadership Fellow. Mr. Booth earned B.S. and M.S. degrees from the University of Hartford Barney School in Connecticut.
Ms. Demski has more than 30 years of experience in the fields of finance and biotechnology. She is on the Board of Directors of Chimerix, Inc., where she chairs the audit committee and serves on the nominating and governance committee, and Neothetics, Inc., where she chairs the audit committee and serves on the compensation committee. Previously Ms. Demski served as Senior Vice President and Chief Financial Officer of Ajinomoto Althea, Inc., prior to that she served as the Interim Chief Operating Officer and Chief Financial Officer of the Sidney Kimmel Cancer Center and before that as Chief Financial Officer of Vical Incorporated where she was responsible for multiple private and public financings, including the company’s initial public offering. Additionally, Ms. Demski has over 13 years of banking experience with Bank of America and U.S. Trust. She holds an M.B.A. from The University of Chicago Booth School of Business and a B.A. from Michigan State University.
Mr. Ericson is a managing partner of Mohr Davidow Ventures and a managing director of Wildcat Venture Partners. He currently serves on the Board of Directors of Pacific Biosciences (Nasdaq: PACB) and Rocket Fuel (Nasdaq: FUEL) as well on the board of a number of privately held software and healthcare companies. Mr. Ericson received his B.S.F.S. from Georgetown University of Foreign Service and his J.D. from Northwestern University School of Law.
Dr. Lieberburg is currently a member of the Tavistock Group, a private equity firm, where he concentrates on healthcare and life sciences investment opportunities. Prior to joining Tavistock in 2009, Dr. Lieberburg was employed at Elan, plc, for 22 years, where his most recently served as Executive Vice President, Corporate Office of Technology and Chief Medical Officer. Prior to joining Elan (formerly Athena Neurosciences, Inc.) in 1987, Dr. Lieberburg held faculty positions at Albert Einstein School of Medicine and Mt. Sinai School of Medicine. He earned a Ph.D. from Rockefeller University, and an M.D. from University of Miami. Dr. Lieberburg is the author on over 100 publications and an inventor on 29 patents and patent applications.
Mr. MacPhee serves as Chief Executive Officer of The JED Foundation, a non-profit organization that exists to reduce the risks of substance abuse, self-harm and suicide and help young adults thrive. Prior to JED, he served as Executive Vice President of Par Pharmaceutical, Inc. and President of Par’s Strativa Pharmaceuticals division, where he oversaw commercial operations, clinical development, medical affairs and business development. Previously, he worked at Forest Laboratories, where he led the launches of Celexa®, Lexapro® and Namenda®. Mr. MacPhee also serves as a board member for Bottom Line, a nonprofit organization that provides guidance counseling to disadvantaged urban youth to help them get into college and graduate. He earned a B.A. from Columbia College, an M.B.A. from New York University and an M.P.H. from Columbia University.
Mr. Mahoney is a private equity investor and currently serves on the Board of Directors of Symantec Corporation, Corcept Therapeutics and Mercy Corps and as a Trustee of the Schwab Mutual Funds and SFMOMA. Previously, Mr. Mahoney acted as co-Chief Executive Officer of McKesson HBOC, Inc. (now McKesson Corporation) and as Chief Executive Officer of McKesson LLC from July 1999 to February 2001. He joined McKesson in 1990 as Vice President for Strategic Planning and managed the company's relationships with the pharmaceutical industry. Prior to joining McKesson, Mr. Mahoney was a principal with McKinsey & Company from 1981 to 1990. Mr. Mahoney is an honors graduate from Harvard Business School and Princeton University.